.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,067,427

« Back to Dashboard

Claims for Patent: 8,067,427

Title:Pharmaceutical compositions comprising ZD6474
Abstract: A pharmaceutical composition comprising ZD6474 or a pharmaceutically acceptable salt thereof, a brittle diluent and a second diluent which is practically insoluble and has ductile compression properties.
Inventor(s): Stott; Paul William (Wilmington, DE)
Assignee: AstraZeneca AB (Sodertajle, SE)
Application Number:11/596,979
Patent Claims: 1. A pharmaceutical composition comprising: (a) 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)qu- inazoline (ZD6474) or a pharmaceutically acceptable salt thereof; (b) a brittle diluent selected from dibasic calcium phosphate, tribasic calcium phosphate, calcium phosphate anhydrous, calcium carbonate, calcium sulphate and magnesium oxide; and (c) a second diluent which is practically insoluble and has ductile compression properties selected from microcrystalline cellulose, starch, ethylcellulose and carboxymethylcellulose.

2. The pharmaceutical composition according to claim 1 wherein the brittle diluent is dibasic calcium phosphate.

3. The pharmaceutical composition according to claim 1 or claim 2 wherein the second diluent which is practically insoluble and has ductile compression properties is microcrystalline cellulose.

4. The pharmaceutical composition according to claim 1 comprising: (a) from 1 to 70 parts 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)qu- inazoline (ZD6474) or a pharmaceutically acceptable salt thereof; (b) from 1 to 96 parts of the brittle diluent; and (c) from 0.1 to 20 parts of the second diluent which is practically insoluble and has ductile compression properties; wherein all parts are by weight and the sum of the parts (a)+(b)+(c)=100.

5. The pharmaceutical composition according to claim 1 comprising: (a) from 5 to 50 parts 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)qu- inazoline (ZD6474) or a pharmaceutically acceptable salt thereof; (b) from 10 to 70 parts of the brittle diluent; and (c) from 1 to 15 parts of the second diluent which is practically insoluble and has ductile compression properties; wherein all parts are by weight and the sum of the parts (a)+(b)+(c)=100.

6. The pharmaceutical composition according to claim 4 or claim 5 wherein the brittle diluent is dibasic calcium phosphate and the second diluent which is practically insoluble and has ductile compression properties is microcrystalline cellulose.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc